leukemia

[Leukemia] Recurrent mutations in IDH1 or IDH2 in acute myeloid leukemia (AML) are associated with increased DNA methylation. Scientists analyzed whole-genome bisulfite sequencing data from 15 primary AML samples with IDH1 or IDH2 mutations,

[Leukemia] By using TL1, a human T-LGL cell line, the authors could show that miR-181a was an actor in T-LGL leukemia, driving STAT3 activation by SOCS3 inhibition and ERK1/2 phosphorylation by DUSP6 inhibition and verified this mechanism in an independent cell line.

[Oncogene] Investigators demonstrated that HMGN1 knockout-mitigated leukemic phenotypes including hepatosplenomegaly, thrombocytopenia, and anemia, were commonly observed in leukemia patients, and significantly increased survival in vivo.

[Proceedings of the National Academy of Sciences of the United States of America] Using exome sequencing, RNA-sequencing, and functional immunologic studies, scientists characterized 28 normal karyotype (NK)-AML patients with over 5 year first remissions after chemotherapy and compared them to a well-matched group of 31 NK-AML patients who relapsed within two years.

[Haematologica] PVRIG blockade significantly enhanced NK-cell killing of poliovirus receptor-related 2 (PVRL2)+, poliovirus receptorlo AML cell lines, and significantly increased NK-cell activation and degranulation in the context of patient primary AML blasts.

[Kura Oncology, Inc.] Kura Oncology, Inc. announced that the US FDA has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia on a partial clinical hold following the company’s recent report of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome.